CoChat
Sign Up
Cited by 334Veterinary Oncology ResearchLung Cancer Research StudiesLung Cancer Diagnosis and Treatment

Classification of Proliferative Pulmonary Lesions of the Mouse

Open access
Nikitin, Alexander Yu., Alcaraz, Ana, Anver, Miriam R., Bronson, Roderick T., Cardiff, Robert D., Dixon, Darlene, Fraire, Armando E., Gabrielson, Edward W. +14 more·2004·Cancer Research
DOI 10.1158/0008-5472.can-03-3376

Published version of a preprint

Open this paper in CoChat — free accountOpen PDF

Abstract

Rapid advances in generating new mouse genetic models for lung neoplasia provide a continuous challenge for pathologists and investigators. Frequently, phenotypes of new models either have no precedents or are arbitrarily attributed according to incongruent human and mouse classifications. Thus, comparative characterization and validation of novel models can be difficult. To address these issues, a series of discussions was initiated by a panel of human, veterinary, and experimental pathologists during the Mouse Models of Human Cancers Consortium (NIH/National Cancer Institute) workshop on mouse models of lung cancer held in Boston on June 20-22, 2001. The panel performed a comparative evaluation of 78 cases of mouse and human lung proliferative lesions, and recommended development of a new practical classification scheme that would (a) allow easier comparison between human and mouse lung neoplasms, (b) accommodate newly emerging mouse neoplasms, and (c) address the interpretation of benign and preinvasive lesions of the mouse lung. Subsequent discussions with additional experts in pulmonary pathology resulted in the current proposal of a new classification. It is anticipated that this classification, as well as the complementary digital atlas of virtual histological slides, will help investigators and pathologists in their characterization of new mouse models, as well as stimulate further research aimed at a better understanding of proliferative lesions of the lung.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-03-3376

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • All tumors from the survival cohort were analyzed on H&E sections and categorized according to the Mouse Models of Human Cancer Consortium recommendations.

    “All tumors from the survival cohort were analyzed on H&E sections and categorized as hyperplasia, atypical adenomatous hyperplasia, adenoma, adenoma with typia, and adenocarcinoma according to the Mouse Models of Human Cancer Consortium recommendations.(Nikitin et al., 2004)”

    From Modulation of K-Ras-Dependent Lung Tumorigenesis by MicroRNA-21 (2010) · cites this paper as Nikitin et al., 2004

    The Development of Recommendations section says the consortium prepared and reviewed H&E-stained sections, and the classification defines hyperplasia, atypical adenomatous hyperplasia, adenoma, and adenocarcinoma. The cited paper does not identify “adenoma with typia” as a recommended category. The survival-cohort analysis describes the citing authors’ own work, not an analysis reported by Nikitin et al. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 86 · Cited by 334

Research works printed but not linked: 78

  1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
  2. Dungworth DL, Rittinghausen S, Schwartz L, et al. Respiratory system and mesothe- lium. In: Mohr U, editor. International classification of rodent tumors. The mouse. Heidelberg: Springer-Verlag; 2001. p 87-137.
  3. Rittinghausen S, Dungworth DI, Ernst H, Mohr U. Primary pulmonary tumors. In: Mohr U, Dungworth DI, Capen CC, Carlton WW, Sundberg JP, Ward JM, editors. Pathobiology of the aging mouse. Vol 1. Washington, DC: International Life Sciences Institute Press; 1996.
  4. Dixon D, Herbert RA, Sills RC, Boorman GA. Lungs, pleura, and mediastinum. In: Maronpot RR, Boorman GA, Gaul BW, editors. Pathology of the mouse. Vienna: Cache River Press; 1999. p. 293-332.
  5. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological typing of lung and Pleural Tumours. 3rd ed. Berlin: Springer Verlag; 1999. p. 156.
  6. Rehm S, Devor DE, Henneman JR, Ward JM. Origin of spontaneous and transpla- centally induced mouse lung tumors from alveolar type II cells. Exp Lung Res 1991;17:181-95.
  7. Foley JF, Anderson MW, Stoner GD, Gaul BW, Hardisty JF, Maronpot RR. Prolif- erative lesions of the mouse lung: progression studies in strain A mice. Exp Lung Res 1991;17:157-68.
  8. Ohshima M, Ward JM, Singh G, Katyal SL. Immunocytochemical and morphological evidence for the origin of N-nitrosomethylurea-induced and naturally occurring primary lung tumors in F344/NCr rats. Cancer Res 1985;45:2785-92.
  9. Fisher GH, Wellen SL, Klimstra D, et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 2001;15:3249 -62.
  10. Shimkin MB, Polissar MJ. Some quantitative observations on the induction and growth of primary pulmonary tumors in strain A mice receiving urethan. J Natl Cancer Res (Bethesda) 1955;16:75-97.
  11. Rehm S, Kelloff GJ. Histologic characterization of mouse bronchiolar cell hyperpla- sia, metaplasia, and neoplasia induced intratracheally by 3-methylcholanthrene. Exp Lung Res 1991;17:229 -44.
  12. Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature (Lond) 2001;410:1111-6.
  13. Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001;15: 3243-8.
  14. Kerr KM. Pulmonary preinvasive neoplasia. J Clin Pathol 2001;54:257-71.
  15. Mori M, Rao SK, Popper HH, Cagle PT, Fraire AE. Atypical adenomatous hyper- plasia of the lung: a probable forerunner in the development of adenocarcinoma of the lung. Mod Pathol 2001;14:72-84.
  16. Kaufman MH, Bard JBL. The anatomical basis of mouse development. San Diego: Academic Press; 1999.
  17. Kaufman MH. The atlas of mouse development. London: Academic Press; 1994.
  18. Hogan BLM, Zaret KS. Development of the endoderm and its tissue derivatives. In: Rossant J, Tam PPL, editors. Mouse development. Patterning, morphogenesis, and organogenesis. San Diego: Academic Press; 2002. p. 301-30.
  19. Hislop AA, Wigglesworth JS, Desai R. Alveolar development in the human fetus and infant. Early Hum Dev 1986;13:1-11.
  20. Geubelle F, Karlberg P, Koch G, Lind J, Wallgren G, Wegelius C. Aeration of the lung in the newborn infant. Biol Neonate 1959;1:169 -210.
  21. Ten Have-Opbroek AA. Lung development in the mouse embryo. Exp Lung Res 1991;17:111-30.
  22. Magdaleno SM, Barrish J, Finegold MJ, DeMayo FJ. Investigating stem cells in the lung. Adv Pediatr 1998;45:363-96.
  23. Emura M. Stem cells of the respiratory tract. Paediatr Respir Rev 2002;3:36 -40.
  24. Otto WR. Lung epithelial stem cells. J Pathol 2002;197:527-35.
  25. Perl AK, Wert SE, Nagy A, Lobe CG, Whitsett JA. Early restriction of peripheral and proximal cell lineages during formation of the lung. Proc Natl Acad Sci USA 2002;99:10482-7.
  26. Tuveson DA, Jacks T. Modeling human lung cancer in mice: similarities and shortcomings. Oncogene 1999;18:5318 -24.
  27. Ward JM, Anver MR, Mahler JF, Devor-Henneman DE. Pathology of mice com- monly used in genetic engineering (C57BL/6; 129; B6,129; and FVB/N). In: Ward JM, Mahler JF, Maronpot RR, Sundberg JP, editors. Pathology of genetically engi- neered mice. Ames, IA: Iowa State University Press; 2000. p. 161-79.
  28. Haines DC, Chattopadhyay S, Ward JM. Pathology of aging B6;129 mice. Toxicol Pathol 2001;29:653-61.
  29. Gunning WT, Castonguay A, Goldblatt PJ, Stoner GD. Strain A/J mouse lung adenoma growth patterns vary when induced by different carcinogens. Toxicol Pathol 1991;19:168 -75.
  30. Ward JM, Singh G, Katyal SL, Anderson LM, Kovatch RM. Immunocytochemical localization of the surfactant apoprotein and Clara cell antigen in chemically induced and naturally occurring pulmonary neoplasms of mice. Am J Pathol 1985;118: 493-99.
  31. Rehm S, Ward JM, Anderson LM, Riggs CW, Rice JM. Transplacental induction of mouse lung tumors: stage of fetal organogenesis in relation to frequency, morphology, size, and neoplastic progression of N-nitrosoethylurea-induced tumors. Toxicol Pathol 1991;19:35-46.
  32. Gunning WT, Kramer PM, Lubet RA, Steele VE, Pereira MA. Chemoprevention of vinyl carbamate-induced lung tumors in strain A mice. Exp Lung Res 2000;26: 757-72.
  33. You M, Candrian U, Maronpot RR, Stoner GD, Anderson MW. Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tu- mors of the strain A mouse. Proc Natl Acad Sci USA 1989;86:3070 -4.
  34. You M, Wang Y, Lineen A, et al. Activation of protooncogenes in mouse lung tumors. Exp Lung Res 1991;17:389 -400.
  35. Herzog CR, Soloff EV, McDoniels AL, et al. Homozygous codeletion and differential decreased expression of p15INK4b, p16INK4a-␣ and p16INK4a-␤ in mouse lung tumor cells. Oncogene 1996;13:1885-91.
  36. Shimkin MB, Stoner GD. Lung tumors in mice: application to carcinogenesis bioas- say. Adv Cancer Res 1975;21:1-58.
  37. Grady HG, Stewart HL. Histogenesis of induced pulmonary tumors in strain A mice. Am J Pathol 1940;16:417-32.
  38. Kimura K. Progression of pulmonary tumor in mice. 1. Histological studies of primary and transplanted pulmonary tumors. Acta Pathol Jpn 1971;21:13-56.
  39. Rehm S, Ward JM, ten Have-Opbroek AA, et al. Mouse papillary lung tumors transplacentally induced by N-nitrosoethylurea: evidence for alveolar type II cell origin by comparative light microscopic, ultrastructural, and immunohistochemical studies. Cancer Res 1988;48:148 -60.
  40. Rehm S, Ward JM. Quantitative analysis of alveolar type II cell tumors in mice by whole lung serial and step sections. Toxicol Pathol 1989;17:737-42.
  41. Mason RJ, Kalina M, Nielsen LD, Malkinson AM, Shannon JM. Surfactant protein C expression in urethane-induced murine pulmonary tumors. Am J Pathol 2000;156: 175-82.
  42. Gunning WT, Goldblatt PJ, Stoner GD. Keratin expression in chemically induced mouse lung adenomas. Am J Pathol 1992;140:109 -18.
  43. Kauffman SL, Alexander L, Sass L. Histologic and ultrastructural features of the Clara cell adenoma of the mouse lung. Lab Investig 1979;40:708 -16.
  44. Kauffman SL. Cell proliferation in the mammalian lung. Int Rev Exp Pathol 1980; 22:131-91.
  45. Kauffman SL. Histogenesis of the papillary Clara cell adenoma. Am J Pathol 1981;103:174 -80.
  46. Dixon D, Horton J, Haseman JK, et al. Histomorphology and ultrastructure of spontaneous pulmonary neoplasms in strain A mice. Exp Lung Res 1991;17:131-55.
  47. Belinsky SA, Devereux TR, White CM, Foley JF, Maronpot RR, Anderson MW. Role of Clara cells and type II cells in the development of pulmonary tumors in rats and mice following exposure to a tobacco-specific nitrosamine. Exp Lung Res 1991;17: 263-78.
  48. Gunning WT, Stoner GD, Goldblatt PJ. Glyceraldehyde-3-phosphate dehydrogenase and other enzymatic activity in normal mouse lung and in lung tumors. Exp Lung Res 1991;17:255-61.
  49. Nettesheim P. Cells of origin of primary pulmonary neoplasms in mice. Exp Lung Res 1991;17:215-7.
  50. Rehm S, Lijinsky W, Singh G, Katyal SL. Mouse bronchiolar cell carcinogenesis. Histologic characterization and expression of Clara cell antigen in lesions induced by N-nitroso-bis-(2-chloroethyl) ureas. Am J Pathol 1991;139:413-22.
  51. Karube T, Katayama H, Takemoto K, Watanabe S. Induction of squamous metapla- sia, dysplasia and carcinoma in situ of the mouse tracheal mucosa by inhalation of sodium chloride mist following subcutaneous injection of 4-nitroquinoline 1-oxide. Jpn J Cancer Res 1989;80:698 -701.
  52. Magdaleno SM, Wang G, Mireles VL, Ray MK, Finegold MJ, DeMayo FJ. Cyclin- dependent kinase inhibitor expression in pulmonary Clara cells transformed with SV40 large T antigen in transgenic mice. Cell Growth Differ 1997;8:145-55.
  53. Hicks SM, Vassallo JD, Dieter MZ, et al. Immunohistochemical analysis of Clara cell secretory protein expression in a transgenic model of mouse lung carcinogenesis. Toxicology 2003;187:217-28.
  54. Maronpot RR, Palmiter RD, Brinster RL, Sandgren EP. Pulmonary carcinogenesis in transgenic mice. Exp Lung Res 1991;17:305-20.
  55. Wikenheiser KA, Clark JC, Linnoila RI, Stahlman MT, Whitsett JA. Simian virus 40 large T antigen directed by transcriptional elements of the human surfactant protein C gene produces pulmonary adenocarcinomas in transgenic mice. Cancer Res 1992; 52:5342-52.
  56. Tichelaar JW, Lu W, Whitsett JA. Conditional expression of fibroblast growth factor-7 in the developing and mature lung. J Biol Chem 2000;275:11858 -64.
  57. Fedorov LM, Papadopoulos T, Tyrsin OY, Twardzik T, Gotz R, Rapp UR. Loss of p53 in craf-induced transgenic lung adenoma leads to tumor acceleration and phe- notypic switch. Cancer Res 2003;63:2268 -77.
  58. Meuwissen R, Linn SC, van der Valk M, Mooi WJ, Berns A. Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. Oncogene 2001;20:6551-8.
  59. Sunday ME, Haley KJ, Sikorski K, et al. Calcitonin driven v-Ha-ras induces multi- lineage pulmonary epithelial hyperplasias and neoplasms. Oncogene 1999;18: 4336 -47.
  60. Wikenheiser KA, Whitsett JA. Tumor progression and cellular differentiation of pulmonary adenocarcinomas in SV40 large T antigen transgenic mice. Am J Respir Cell Mol Biol 1997;16:713-23.
  61. Linnoila RI, Zhao B, DeMayo JL, et al. Constitutive achaete-scute homologue-1 promotes airway dysplasia and lung neuroendocrine tumors in transgenic mice. Cancer Res 2000;60:4005-9.
  62. Borges M, Linnoila RI, van de Velde HJ, et al. An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature (Lond) 1997;386:852-5.
  63. Clark JC, Tichelaar JW, Wert SE, et al. FGF-10 disrupts lung morphogenesis and causes pulmonary adenomas in vivo. Am J Physiol Lung Cell Mol Physiol 2001;280: L705-15.
  64. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet 1994;7:480 -4.
  65. Nikitin AY, Jua ´rez-Pe ´rez MI, Li S, Huang L, Lee, W-H. RB-mediated suppression of multiple neuroendocrine neoplasia and lung metastases in Rb ϩ/Ϫ mice. Proc Natl Acad Sci USA 1999;96:3916 -21.
  66. Linnoila RI, Sahu A, Miki M, Ball DW, DeMayo FJ. Morphometric analysis of CC10-hASH1 transgenic mouse lung: a model for bronchiolization of alveoli and neuroendocrine carcinoma. Exp Lung Res 2000;26:595-615.
  67. Zhao B, Chua SS, Burcin MM, et al. Phenotypic consequences of lung-specific inducible expression of FGF-3. Proc Natl Acad Sci USA 2001;98:5898 -903.
  68. Jonkers J, Berns A. Conditional mouse models of sporadic cancer. Nat Rev. Cancer 2002;2:251-65.
  69. Nikitin AY, Riley DJ, Lee W-H. A paradigm for cancer treatment using the retino- blastoma gene in a mouse model Ann NY Acad Sci 1999;886:12-22.
  70. Gariboldi M, Manenti G, Canzian F, et al. A major susceptibility locus to murine lung carcinogenesis maps on chromosome 6. Nat Genet 1993;3:132-6.
  71. Manenti G, Gariboldi M, Elango R, et al. Genetic mapping of a pulmonary adenoma resistance (Par1) in mouse. Nat Genet 1996;12:455-7.
  72. Wang M, Lemon WJ, Liu G, et al. Fine mapping and identification of candidate pulmonary adenoma susceptibility 1 genes using advanced intercross lines. Cancer Res 2003;63:3317-24.
  73. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma sub- classes. Proc Natl Acad Sci USA 2001;98:13790 -5.
  74. Podsypanina K, Ellenson LH, Nemes A, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999;96:1563-8.
  75. Suzuki A, de la Pompa JL, Stambolic V, et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998;8:1169 -78.
  76. Zhao B, Magdaleno S, Chua S, et al. Transgenic mouse models for lung cancer. Exp Lung Res 2000;26:567-79.
  77. Sandgren EP, Quaife CJ, Pinkert CA, Palmiter RD, Brinster RL. Oncogene-induced liver neoplasia in transgenic mice. Oncogene 1989;4:715-24.
  78. Zhang Z, Wang Y, Vikis HG, et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet 2001;29:25-33.

Authors
Nikitin, A. Y., Alcaraz, A., Anver, M. R., Bronson, R. T., Cardiff, R. D., Dixon, D., Fraire, A. E., Gabrielson, E. W., Gunning, W. T., Haines, D. C., Kaufman, M. H., Linnoila, R. I., Maronpot, R. R., Rabson, A. S., Reddick, R. L., Rehm, S., Rozengurt, N., Schuller, H. M., Shmidt, E. N., Travis, W. D., Ward, J. M., & Jacks, T.
Affiliations
  • Cornell University (US)
  • National Institutes of Health (US)
  • Tufts University (US)
  • University of California, Davis (US)
  • National Institute of Environmental Health Sciences (US)
  • University of Massachusetts Chan Medical School (US)
  • Johns Hopkins University (US)
  • University of Toledo Medical Center (US)
  • University of Edinburgh (GB)
  • The University of Texas at San Antonio Health Science Center (US)
  • GlaxoSmithKline (United States) (US)
  • University of California, Los Angeles (US)
  • University of Tennessee at Knoxville (US)
  • Armed Forces Institute of Pathology (US)
  • Howard Hughes Medical Institute (US)
ORCID
Venue
Cancer Research
Publisher
American Association for Cancer Research (AACR)
Published
2004-04-01
Volume
64
Issue
7
Pages
2307-2316
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
DOI
10.1158/0008-5472.can-03-3376
OpenAlex
W2158777030
Cited by
334
References
86
Citations by year
2026: 2 · 2025: 13 · 2024: 11 · 2023: 10 · 2022: 5 · 2021: 15 · 2020: 12 · 2019: 17 · 2018: 22 · 2017: 13 · 2016: 11 · 2015: 21 · 2014: 19 · 2013: 26 · 2012: 21
FWCI
2.59
Type
journal article
Language
en
Open access
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
Funders
  • Massachusetts Institute of Technology
  • University of Pennsylvania
  • Memorial Sloan-Kettering Cancer Center
  • Baylor University
  • National Institutes of Health (5u01ca084241-02)
  • U.S. Public Health Service (N01-C0-124000)
  • University of California, Davis
  • National Cancer Institute (CA84241, CA84242, U01CA084242)
  • National Center for Research Resources (RR017595, K26RR017595)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Veterinary Oncology Research
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords
histological classification, preinvasive lung lesions, benign lung lesions
MeSH terms
Animals, Disease Models, Animal, Humans, Lung Neoplasms, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review